Document is current
Any future updates will be listed below
-
Authors
Yu, Shirley P. https://orcid.org/0000-0002-2223-2182
Deveza, Leticia A.
Kraus, Virginia B.
Karsdal, Morten
Bay-Jensen, Anne-Christine
Collins, Jamie E.
Guermazi, Ali
Roemer, Frank W.
Ladel, Christoph
Bhagavath, Venkatesha
Hunter, David J.
-
Funding
Funding for this research was provided by:
University of Sydney (Postgraduate Scholarship (Merck PhD Scholarship in Medicine))
Foundation for the National Institutes of Health
National Institutes of Health (NIAMS K01AR075879)
Else Kröner-Fresenius-Stiftung
Nordic Bioscience
National Health and Medical Research Council (Investigator Fellowship)
- License Information
-
More Information
Article History
Received: 20 July 2023
Accepted: 27 December 2023
First Online: 18 January 2024
Declarations
:
: The OAI study received ethical approval from each OAI clinical site and for the OAI coordinating center. All participants provided informed consent to the OAI.
: Not applicable.
: DJH provides consulting advice to Merck Serono, Pfizer, Lilly, TLCBio, Novartis.VBK provides consulting advice to 23andME, Bioiberica, Genascence, Novartis, Paradigm Biopharma.AG provides consulting to Pfizer, Novartis, TrialSpark, ICM, Coval, Medipost and AstraZeneca. He is Shareholder of BICL, LLC.FR is consultant to Grünenthal, GmbH and shareholder of Boston Imaging Core Lab (BICL), LLC.JEC provides consulting to BICL, LLC.CL provides consulting advice to Charité, TrialSpark, Regenosine and ReumaNederland.MK and AB are full-time employee and shareholders of Nordic Bioscience.Other authors declare that they did not have any competing interests.
